Iclusig (ponatinib) — Medica

Initial criteria

• Patient age ≥ 18 years
• Patient has Philadelphia chromosome-positive chronic myeloid leukemia OR BCR::ABL1-positive chronic myeloid leukemia
• The chronic myeloid leukemia is T315I-positive OR patient has tried at least one other tyrosine kinase inhibitor (e.g., imatinib, dasatinib, Danziten [nilotinib tablets], Tasigna [nilotinib capsules], or Nilotinib capsules) OR patient has accelerated-phase or blast-phase CML and no other tyrosine kinase inhibitor is indicated

Approval duration

1 year